Skip to main content
. 2022 Aug;15(8):E53–E60.

FIGURE 3.

FIGURE 3.

TriHex™ protects against telomere shortening in fibroblasts. Human primary neonatal fibroblasts were treated with the RSC formulation at 100, 50, and 3μg/mL for six weeks. The TAT assay was conducted to determine the telomere lengths. Then, the telomere shortening rate was determined by the following formula: median telomere length (initial-final)/population doubling. The values were compared, and the data represent the mean±SD. **** p<0.0001